European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim (EMA press release, 23 September 2010)

23 Sept 2010

The European Medicines Agency has recommended that marketing authorisation for the diabetes drug Avandia (generic name rosiglitazone) and its combination therapies be suspended following a review of data on the drug's cardiovascular side-effects.